Biosimilar breast cancer drug trial halted midway
NCT ID NCT06038539
First seen Mar 18, 2026 · Last updated May 23, 2026 · Updated 6 times
Summary
This study tested whether a new biosimilar drug (PERT-IJS) works as well as the approved drug Perjeta® for treating a certain type of breast cancer (HER2-positive, hormone receptor-negative). About 55 women with early or locally advanced breast cancer were to receive either the biosimilar or Perjeta® along with standard chemotherapy before surgery. The goal was to see if the biosimilar could achieve a similar rate of complete tumor disappearance. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR NEGATIVE HER2 POSITIVE EARLY BREAST CANCER OR LOCALLY ADVANCED BREAST CANCER PATIENTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chopda Medicare & Research Centre Pvt. Ltd,
Nashik, 422005, India
Conditions
Explore the condition pages connected to this study.